Colorectal cancer stem cells and cell death

Cancers

Volumn 3, Issue 2, 2011, Pages 1929-1946

  Catalano, Veronica ^a   Gaggianesi, Miriam ^a,b   Spina, Valentina ^a   Iovino, Flora ^a   Dieli, Francesco ^c   Stassi, Giorgio ^a,b   Todaro, Matilde ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apoptosis; BMP4; Cancer stem cells; Surviving

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 4; CD133 ANTIGEN; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; HERMES ANTIGEN; INTERLEUKIN 4; IRINOTECAN; OXALIPLATIN; PROTEIN BCL 2; PROTEIN INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SURVIVIN; SURVIVIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

APOPTOSIS; AUTOCRINE EFFECT; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CHEMOSENSITIVITY; COLON CANCER; COLORECTAL CANCER; CYTOKINE PRODUCTION; DNA DAMAGE; HUMAN; MULTIPOTENT STEM CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 79959747636     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3021929     Document Type: Review

References (98)

1. Sengupta, A.; Cancelas, J.A. Cancer stem cells: A stride towards cancer cure? J. Cell Physiol. 225, 7-14.
2. Heppner, G.H. Tumor heterogeneity. Cancer Res. 1984, 44, 2259-2265.
3. Dick, J.E. Stem cell concepts renew cancer research. Blood 2008, 112, 4793-4807.
4. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
5. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65, 10946-10951.
6. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401.
7. Dalerba, P.; Dylla, S.J.; Park, I.K.; Liu, R.; Wang, X.; Cho, R.W.; Hoey, T.; Gurney, A.; Huang, E.H.; Simeone, D.M.; Shelton, A.A.; Parmiani, G.; Castelli, C.; Clarke, M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104, 10158-10163.
8. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67, 1030-1037.
9. Suzuki, S.; Terauchi, M.; Umezu, T.; Kajiyama, H.; Shibata, K.; Nawa, A.; Kikkawa, F. Identification and characterization of cancer stem cells in ovarian yolk sac tumors. Cancer Sci. 2010, 101, 2179-2185.
10. Eramo, A.; Haas, T.L.; De Maria, R. Lung cancer stem cells: Tools and targets to fight lung cancer. Oncogene 2010, 29, 4625-4635.
11. Todaro, M.; Iovino, F.; Eterno, V.; Cammareri, P.; Gambara, G.; Espina, V.; Gulotta, G.; Dieli, F.; Giordano, S.; De Maria, R.; Stassi, G. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 2010, 70, 8874-8885.
12. Alison, M.R.; Islam, S.; Wright, N.A. Stem cells in cancer: Instigators and propagators? J. Cell Sci. 123, 2357-2368.
13. Todaro, M.; Francipane, M.G.; Medema, J.P.; Stassi, G. Colon cancer stem cells: Promise of targeted therapy. Gastroenterology 2010, 138, 2151-2162.
14. O'Brien, C.A.; Kreso, A.; Jamieson, C.H. Cancer stem cells and self-renewal. Clin. Cancer Res. 2010, 16, 3113-3120.
15. Kosinski, C.; Li, V.S.; Chan, A.S.; Zhang, J.; Ho, C.; Tsui, W.Y.; Chan, T.L.; Mifflin, R.C.; Powell, D.W.; Yuen, S.T.; Leung, S.Y.; Chen, X. Gene expression patterns of human colon tops and basal crypts and bmp antagonists as intestinal stem cell niche factors. Proc. Natl. Acad. Sci. USA 2007, 104, 15418-15423.
16. Holmberg, J.; Genander, M.; Halford, M.M.; Anneren, C.; Sondell, M.; Chumley, M.J.; Silvany, R.E.; Henkemeyer, M.; Frisen, J. Ephb receptors coordinate migration and proliferation in the intestinal stem cell niche. Cell 2006, 125, 1151-1163.
17. Arends, J.W. Molecular interactions in the vogelstein model of colorectal carcinoma. J. Pathol. 2000, 190, 412-416.
18. van den Brink, G.R.; Offerhaus, G.J. The morphogenetic code and colon cancer development. Cancer Cell 2007, 11, 109-117.
19. Vogelstein, B.; Fearon, E.R.; Hamilton, S.R.; Kern, S.E.; Preisinger, A.C.; Leppert, M.; Nakamura, Y.; White, R.; Smits, A.M.; Bos, J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319, 525-532.
20. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem cells--perspectives on current status and future directions: Aacr workshop on cancer stem cells. Cancer Res. 2006, 66, 9339-9344.
21. O'Brien, C.A.; Pollett, A.; Gallinger, S.; Dick, J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445, 106-110.
22. Ricci-Vitiani, L.; Lombardi, D.G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445, 111-115.
23. Francipane, M.G.; Alea, M.P.; Lombardo, Y.; Todaro, M.; Medema, J.P.; Stassi, G. Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res. 2008, 68, 4022-4025.
24. Shmelkov, S.V.; Butler, J.M.; Hooper, A.T.; Hormigo, A.; Kushner, J.; Milde, T.; St Clair, R.; Baljevic, M.; White, I.; Jin, D.K.; Chadburn, A.; Murphy, A.J.; Valenzuela, D.M.; Gale, N.W.; Thurston, G.; Yancopoulos, G.D.; D'Angelica, M.; Kemeny, N.; Lyden, D.; Rafii, S. Cd133 expression is not restricted to stem cells, and both cd133+ and cd133- metastatic colon cancer cells initiate tumors. J. Clin. Invest. 2008, 118, 2111-2120.
25. Barker, N.; van Es, J.H.; Kuipers, J.; Kujala, P.; van den Born, M.; Cozijnsen, M.; Haegebarth, A.; Korving, J.; Begthel, H.; Peters, P.J.; Clevers, H. Identification of stem cells in small intestine and colon by marker gene lgr5. Nature 2007, 449, 1003-1007.
26. Huang, E.H.; Hynes, M.J.; Zhang, T.; Ginestier, C.; Dontu, G.; Appelman, H.; Fields, J.Z.; Wicha, M.S.; Boman, B.M. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (sc) and tracks sc overpopulation during colon tumorigenesis. Cancer Res. 2009, 69, 3382-3389.
27. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
28. Walczak, H.; Haas, T.L. Biochemical analysis of the native trail death-inducing signaling complex. Methods Mol. Biol. 2008, 414, 221-239.
29. Kischkel, F.C.; Lawrence, D.A.; Chuntharapai, A.; Schow, P.; Kim, K.J.; Ashkenazi, A. Apo2l/trail-dependent recruitment of endogenous fadd and caspase-8 to death receptors 4 and 5. Immunity 2000, 12, 611-620.
30. Verhagen, A.M.; Ekert, P.G.; Pakusch, M.; Silke, J.; Connolly, L.M.; Reid, G.E.; Moritz, R.L.; Simpson, R.J.; Vaux, D.L. Identification of diablo, a mammalian protein that promotes apoptosis by binding to and antagonizing iap proteins. Cell 2000, 102, 43-53.
31. Fukuda, S.; Pelus, L.M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow cd34(+) cells by hematopoietic growth factors: Implication of survivin expression in normal hematopoiesis. Blood 2001, 98, 2091-2100.
32. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444, 756-760.
33. Dutton, A.; Young, L.S.; Murray, P.G. The role of cellular flice inhibitory protein (c-flip) in the pathogenesis and treatment of cancer. Expert Opin. Ther. Targets 2006, 10, 27-35.
34. Fulda, S.; Pervaiz, S. Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol 42, 31-38.
35. Ricci-Vitiani, L.; Pedini, F.; Mollinari, C.; Condorelli, G.; Bonci, D.; Bez, A.; Colombo, A.; Parati, E.; Peschle, C.; De Maria, R. Absence of caspase 8 and high expression of ped protect primitive neural cells from cell death. J. Exp. Med. 2004, 200, 1257-1266.
36. Ashkenazi, A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 2008, 7, 1001-1012.
37. Capper, D.; Gaiser, T.; Hartmann, C.; Habel, A.; Mueller, W.; Herold-Mende, C.; von Deimling, A.; Siegelin, M.D. Stem-cell-like glioma cells are resistant to trail/apo2l and exhibit downregulation of caspase-8 by promoter methylation. Acta Neuropathol. 2009, 117, 445-456.
38. Todaro, M.; Perez Alea, M.; Scopelliti, A.; Medema, J.P.; Stassi, G. Il-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008, 7, 309-313.
39. Verdecia, M.A.; Huang, H.; Dutil, E.; Kaiser, D.A.; Hunter, T.; Noel, J.P. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 2000, 7, 602-608.
40. Chantalat, L.; Skoufias, D.A.; Kleman, J.P.; Jung, B.; Dideberg, O.; Margolis, R.L. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol. Cell 2000, 6, 183-189.
41. Li, F. Role of survivin and its splice variants in tumorigenesis. Br. J. Cancer 2005, 92, 212-216.
42. Mirza, A.; McGuirk, M.; Hockenberry, T.N.; Wu, Q.; Ashar, H.; Black, S.; Wen, S.F.; Wang, L.; Kirschmeier, P.; Bishop, W.R.; Nielsen, L.L.; Pickett, C.B.; Liu, S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002, 21, 2613-2622.
43. Badran, A.; Yoshida, A.; Ishikawa, K.; Goi, T.; Yamaguchi, A.; Ueda, T.; Inuzuka, M. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem. Biophys. Res. Commun. 2004, 314, 902-907.
44. Li, F.; Ambrosini, G.; Chu, E.Y.; Plescia, J.; Tognin, S.; Marchisio, P.C.; Altieri, D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396, 580-584.
45. Deveraux, Q.L.; Reed, J.C. Iap family proteins--suppressors of apoptosis. Genes Dev. 1999, 13, 239-252.
46. Engelsma, D.; Rodriguez, J.A.; Fish, A.; Giaccone, G.; Fornerod, M. Homodimerization antagonizes nuclear export of survivin. Traffic 2007, 8, 1495-1502.
47. Wall, N.R.; O'Connor, D.S.; Plescia, J.; Pommier, Y.; Altieri, D.C. Suppression of surviving phosphorylation on thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003, 63, 230-235.
48. O'Connor, D.S.; Grossman, D.; Plescia, J.; Li, F.; Zhang, H.; Villa, A.; Tognin, S.; Marchisio, P.C.; Altieri, D.C. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. USA 2000, 97, 13103-13107.
49. Lens, S.M.; Wolthuis, R.M.; Klompmaker, R.; Kauw, J.; Agami, R.; Brummelkamp, T.; Kops, G.; Medema, R.H. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J. 2003, 22, 2934-2947.
50. Kaitna, S.; Mendoza, M.; Jantsch-Plunger, V.; Glotzer, M. Incenp and an aurora-like kinase form a complex essential for chromosome segregation and efficient completion of cytokinesis. Curr. Biol. 2000, 10, 1172-1181.
51. Altieri, D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8, 61-70.
52. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3, 917-921.
53. Mahotka, C.; Wenzel, M.; Springer, E.; Gabbert, H.E.; Gerharz, C.D. Survivin-deltaex3 and survivin-2b: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999, 59, 6097-6102.
54. Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D.A.; Vigna, N.; Oltersdorf, T.; Reed, J.C. Iapfamily protein survivin inhibits caspase activity and apoptosis induced by fas (cd95), bax, caspases, and anticancer drugs. Cancer Res. 1998, 58, 5315-5320.
55. Azuhata, T.; Scott, D.; Griffith, T.S.; Miller, M.; Sandler, A.D. Survivin inhibits apoptosis induced by trail, and the ratio between survivin and trail receptors is predictive of recurrent disease in neuroblastoma. J. Pediatr. Surg. 2006, 41, 1431-1440.
56. Dohi, T.; Okada, K.; Xia, F.; Wilford, C.E.; Samuel, T.; Welsh, K.; Marusawa, H.; Zou, H.; Armstrong, R.; Matsuzawa, S.; Salvesen, G.S.; Reed, J.C.; Altieri, D.C. An iap-iap complex inhibits apoptosis. J. Biol. Chem. 2004, 279, 34087-34090.
57. Wang, Z.; Fukuda, S.; Pelus, L.M. Survivin regulates the p53 tumor suppressor gene family. Oncogene 2004, 23, 8146-8153.
58. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296-299.
59. Chen, L.; Marechal, V.; Moreau, J.; Levine, A.J.; Chen, J. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J. Biol. Chem. 1997, 272, 22966-22973.
60. Hoffman, W.H.; Biade, S.; Zilfou, J.T.; Chen, J.; Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 2002, 277, 3247-3257.
61. Zhang, T.; Otevrel, T.; Gao, Z.; Ehrlich, S.M.; Fields, J.Z.; Boman, B.M. Evidence that apc regulates survivin expression: A possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 2001, 61, 8664-8667.
62. Klaus, A.; Birchmeier, W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 2008, 8, 387-398.
63. Radtke, F.; Raj, K. The role of notch in tumorigenesis: Oncogene or tumour suppressor? Nat. Rev. Cancer 2003, 3, 756-767.
64. Lee, C.W.; Raskett, C.M.; Prudovsky, I.; Altieri, D.C. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008, 68, 5273-5281.
65. Nelms, K.; Keegan, A.D.; Zamorano, J.; Ryan, J.J.; Paul, W.E. The il-4 receptor: Signaling mechanisms and biologic functions. Annu. Rev. Immunol. 1999, 17, 701-738.
66. Di Stefano, A.B.; Iovino, F.; Lombardo, Y.; Eterno, V.; Hoger, T.; Dieli, F.; Stassi, G.; Todaro, M. Survivin is regulated by interleukin-4 in colon cancer stem cells. J. Cell Physiol. 2010, 225, 555-561.
67. Croci, D.O.; Cogno, I.S.; Vittar, N.B.; Salvatierra, E.; Trajtenberg, F.; Podhajcer, O.L.; Osinaga, E.; Rabinovich, G.A.; Rivarola, V.A. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J. Cell Biochem. 2008, 105, 381-390.
68. Chen, D.; Zhao, M.; Mundy, G.R. Bone morphogenetic proteins. Growth Factors 2004, 22, 233-241.
69. Miyazono, K.; Kamiya, Y.; Morikawa, M. Bone morphogenetic protein receptors and signal transduction. J. Biochem. 2010, 147, 35-51.
70. Zeng, S.; Chen, J.; Shen, H. Controlling of bone morphogenetic protein signaling. Cell. Signal. 2010, 22, 888-893.
71. Rider, C.C.; Mulloy, B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem. J. 2010, 429, 1-12.
72. Wozney, J.M.; Rosen, V.; Celeste, A.J.; Mitsock, L.M.; Whitters, M.J.; Kriz, R.W.; Hewick, R.M.; Wang, E.A. Novel regulators of bone formation: Molecular clones and activities. Science 1988, 242, 1528-1534.
73. Ray, R.P.; Arora, K.; Nusslein-Volhard, C.; Gelbart, W.M. The control of cell fate along the dorsal-ventral axis of the drosophila embryo. Development 1991, 113, 35-54.
74. Jones, C.M.; Lyons, K.M.; Lapan, P.M.; Wright, C.V.; Hogan, B.L. Dvr-4 (bone morphogenetic protein-4) as a posterior-ventralizing factor in xenopus mesoderm induction. Development 1992, 115, 639-647.
75. Zhang, H.; Bradley, A. Mice deficient for bmp2 are nonviable and have defects in amnion/chorion and cardiac development. Development 1996, 122, 2977-2986.
76. Winnier, G.; Blessing, M.; Labosky, P.A.; Hogan, B.L. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 1995, 9, 2105-2116.
77. Mishina, Y.; Suzuki, A.; Ueno, N.; Behringer, R.R. Bmpr encodes a type i bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev. 1995, 9, 3027-3037.
78. Beppu, H.; Kawabata, M.; Hamamoto, T.; Chytil, A.; Minowa, O.; Noda, T.; Miyazono, K. Bmp type ii receptor is required for gastrulation and early development of mouse embryos. Dev. Biol. 2000, 221, 249-258.
79. Yang, X.; Li, C.; Xu, X.; Deng, C. The tumor suppressor smad4/dpc4 is essential for epiblast proliferation and mesoderm induction in mice. Proc. Natl. Acad. Sci. USA 1998, 95, 3667-3672.
80. Chang, H.; Huylebroeck, D.; Verschueren, K.; Guo, Q.; Matzuk, M.M.; Zwijsen, A. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development 1999, 126, 1631-1642.
81. Pera, M.F.; Andrade, J.; Houssami, S.; Reubinoff, B.; Trounson, A.; Stanley, E.G.; Ward-van Oostwaard, D.; Mummery, C. Regulation of human embryonic stem cell differentiation by bmp-2 and its antagonist noggin. J. Cell Sci. 2004, 117, 1269-1280.
82. Sneddon, J.B.; Werb, Z. Location, location, location: The cancer stem cell niche. Cell Stem Cell 2007, 1, 607-611.
83. He, X.C.; Zhang, J.; Tong, W.G.; Tawfik, O.; Ross, J.; Scoville, D.H.; Tian, Q.; Zeng, X.; He, X.; Wiedemann, L.M.; Mishina, Y.; Li, L. Bmp signaling inhibits intestinal stem cell self-renewal through suppression of wnt-beta-catenin signaling. Nat. Genet. 2004, 36, 1117-1121.
84. Howe, J.R.; Roth, S.; Ringold, J.C.; Summers, R.W.; Jarvinen, H.J.; Sistonen, P.; Tomlinson, I.P.; Houlston, R.S.; Bevan, S.; Mitros, F.A.; Stone, E.M.; Aaltonen, L.A. Mutations in the smad4/dpc4 gene in juvenile polyposis. Science 1998, 280, 1086-1088.
85. Howe, J.R.; Bair, J.L.; Sayed, M.G.; Anderson, M.E.; Mitros, F.A.; Petersen, G.M.; Velculescu, V.E.; Traverso, G.; Vogelstein, B. Germline mutations of the gene encoding bone morphogenetic protein receptor 1a in juvenile polyposis. Nat. Genet. 2001, 28, 184-187.
86. Lubbe, S.J.; Pittman, A.M.; Matijssen, C.; Twiss, P.; Olver, B.; Lloyd, A.; Qureshi, M.; Brown, N.; Nye, E.; Stamp, G.; Blagg, J.; Houlston, R.S. Evaluation of germline bmp4 mutation as a cause of colorectal cancer. Hum. Mutat. 2011, 32, E1928-E1938.
87. Haramis, A.P.; Begthel, H.; van den Born, M.; van Es, J.; Jonkheer, S.; Offerhaus, G.J.; Clevers, H. De novo crypt formation and juvenile polyposis on bmp inhibition in mouse intestine. Science 2004, 303, 1684-1686.
88. Hardwick, J.C.; Kodach, L.L.; Offerhaus, G.J.; van den Brink, G.R. Bone morphogenetic protein signalling in colorectal cancer. Nat. Rev. Cancer 2008, 8, 806-812.
89. Massague, J. Tgfbeta in cancer. Cell 2008, 134, 215-230.
90. Thiagalingam, S.; Lengauer, C.; Leach, F.S.; Schutte, M.; Hahn, S.A.; Overhauser, J.; Willson, J.K.; Markowitz, S.; Hamilton, S.R.; Kern, S.E.; Kinzler, K.W.; Vogelstein, B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet. 1996, 13, 343-346.
91. Kodach, L.L.; Wiercinska, E.; de Miranda, N.F.; Bleuming, S.A.; Musler, A.R.; Peppelenbosch, M.P.; Dekker, E.; van den Brink, G.R.; van Noesel, C.J.; Morreau, H.; Hommes, D.W.; Ten Dijke, P.; Offerhaus, G.J.; Hardwick, J.C. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 2008, 134, 1332-1341.
92. Hardwick, J.C.; Van Den Brink, G.R.; Bleuming, S.A.; Ballester, I.; Van Den Brande, J.M.; Keller, J.J.; Offerhaus, G.J.; Van Deventer, S.J.; Peppelenbosch, M.P. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 2004, 126, 111-121.
93. Nishanian, T.G.; Kim, J.S.; Foxworth, A.; Waldman, T. Suppression of tumorigenesis and activation of wnt signaling by bone morphogenetic protein 4 in human cancer cells. Cancer Biol. Ther. 2004, 3, 667-675.
94. Loh, K.; Chia, J.A.; Greco, S.; Cozzi, S.J.; Buttenshaw, R.L.; Bond, C.E.; Simms, L.A.; Pike, T.; Young, J.P.; Jass, J.R.; Spring, K.J.; Leggett, B.A.; Whitehall, V.L. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes hromosomes Cancer 2008, 47, 449-460.
95. Piccirillo, S.G.; Reynolds, B.A.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; Dimeco, F.; Vescovi, A.L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444, 761-765.
96. Lee, J.; Son, M.J.; Woolard, K.; Donin, N.M.; Li, A.; Cheng, C.H.; Kotliarova, S.; Kotliarov, Y.; Walling, J.; Ahn, S.; Kim, M.; Totonchy, M.; Cusack, T.; Ene, C.; Ma, H.; Su, Q.; Zenklusen, J.C.; Zhang, W.; Maric, D.; Fine, H.A. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008, 13, 69-80.
97. Chirasani, S.R.; Sternjak, A.; Wend, P.; Momma, S.; Campos, B.; Herrmann, I.M.; Graf, D.; Mitsiadis, T.; Herold-Mende, C.; Besser, D.; Synowitz, M.; Kettenmann, H.; Glass, R. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 2010, 133, 1961-1972.
98. Lombardo, Y.; Scopelliti, A.; Cammareri, P.; Todaro, M.; Iovino, F.; Ricci-Vitiani, L.; Gulotta, G.; Dieli, F.; De Maria, R.; Stassi, G. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 2011, 1, 297-309.